Background
This case arose from the aftermath of the Supreme Court’s landmark 2021 decision in United States v. Arthrex, Inc., which held that the Patent Trial and Appeal Board’s (PTAB) Administrative Patent Judges (APJs) exercised too much unchecked power in a way that violated the Appointments Clause of the Constitution. The Supreme Court’s remedy was to give the Director of the USPTO authority to review and override PTAB final written decisions — making the Director an accountable principal officer who could provide oversight of APJ rulings.
CyWee Group Ltd. had been the patent owner in two IPR proceedings initiated by Google. PTAB’s APJs found all of CyWee’s challenged patent claims unpatentable for obviousness in January 2020. CyWee raised Appointments Clause objections throughout the litigation. The Federal Circuit had initially affirmed the PTAB decisions in March 2021 — just days before the Supreme Court issued Arthrex. CyWee then sought rehearing from the USPTO Director, arguing that the Director was obligated to review the decisions and that the IPR statutory time limits (which typically require PTAB to complete proceedings within 12-18 months of institution) applied to limit when the Director could act. The Director denied rehearing, and CyWee appealed.
The Court’s Holding
The Federal Circuit affirmed the Director’s denial of rehearing. The court rejected CyWee’s central argument that the IPR statutory deadlines — specifically the requirements in 35 U.S.C. §§ 314(b) and 316(a)(11) governing when institution decisions and final written decisions must occur — constrain the Director’s authority to review PTAB decisions after those deadlines have passed. The court reasoned that the Arthrex remedy was designed to cure a constitutional defect by creating a mechanism for principal officer oversight; the statutory deadlines were directed at the underlying IPR proceeding timeline, not at the Director’s supervisory review authority.
The court also rejected CyWee’s argument that the Appointments Clause itself entitled the patent owner to a meaningful opportunity for Director review within a defined time period. The court explained that the Appointments Clause was designed to prevent inferior officers from exercising unchecked authority — it protects the structural integrity of government by ensuring accountability, not to create procedural rights for private litigants. CyWee had no constitutional entitlement to Director rehearing within any particular timeframe; the Arthrex remedy gave the Director the power to review PTAB decisions, but that power was created for structural accountability purposes, not for the benefit of patent litigation parties.
Key Takeaways
- The IPR statutory deadlines governing institution and final written decisions do not limit or constrain the USPTO Director’s authority to review PTAB decisions under the Arthrex regime.
- The Appointments Clause’s structural remedy (Director review) does not create procedural rights for private parties — patent owners cannot invoke it to demand timely Director review as an entitlement.
- The Arthrex remedy is an accountability mechanism for the executive branch, not a procedural guarantee for litigants.
- Patent owners who obtained adverse PTAB decisions before Arthrex was decided should not expect Director review to be a reliable escape valve — the Director has broad discretion over whether and when to exercise review authority.
Why It Matters
The Arthrex decision generated enormous uncertainty about the scope and mechanics of Director review in the years following 2021. Patent owners who lost at PTAB sought Director review as a potential second chance, often arguing that the constitutional remedy entitled them to meaningful oversight. This decision significantly narrows that avenue: the Director’s review authority is not subject to IPR statutory deadlines, and patent owners have no constitutional right to demand Director review on any particular timeline.
For companies involved in IPR proceedings — both patent owners defending their patents and petitioners challenging them — this ruling clarifies that Director review under Arthrex remains a discretionary tool of the Director, not a procedural entitlement. The decision is part of a broader body of post-Arthrex case law that the Federal Circuit has been developing to cabin the scope of the constitutional remedy while preserving PTAB’s efficiency as an invalidity-challenge forum. Patent owners seeking Director review should focus on presenting compelling substantive grounds for the Director to exercise discretionary authority, rather than relying on procedural arguments about statutory time limits.